Loading
RinuaGene develops mRNA medicines. Its lead product, RG002, is a therapeutic vaccine meant to make the immune system clear cervical precancer caused by HPV types 16 and 18, before it can turn into cancer.
RinuaGene Biotechnology Co., Ltd., in BioBay Industry Park, Suzhou Industrial Park, China, was founded in 2021, according to the company, to develop RNA therapeutics and vaccines on an end-to-end mRNA and lipid nanoparticle platform. Its lead programme RG002 Injection is a therapeutic HPV mRNA vaccine for HPV-associated high-grade squamous intraepithelial lesions, persistent HPV infection and HPV-associated cancers; the company announced US FDA clearance followed by China NMPA CDE IND approval in December 2024. A phase 1/2 study in HPV 16- or 18-associated cervical intraepithelial neoplasia grade 2 or 3 is registered (NCT06273553). Related products RG002-02 to RG002-04 target the same lesions and respiratory papillomatosis, and the company also lists protein-replacement and prophylactic influenza and RSV vaccine programmes. In October 2026 it announced a collaboration with the Medicines Patent Pool under the WHO-led mRNA technology transfer programme. Founded in 2021, according to the company. Its first registered study, NCT06273553, in cervical precancer, was posted on ClinicalTrials.gov in February 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/